What’s New

Secretory carcinoma as a new type of lacrimal gland carcinoma

This study explores the possibility that lacrimal secretory carcinoma exist, but may be misclassified as other tumor types. Source: AAO

Posted on: Oct 4 2018
By: Saratoga Opthalmology
Leave a response

Clinical and radiological evaluations show poor accuracy for diagnosing orbital lesions

This study compares the accuracy of clinical and radiological diagnoses versus histological diagnoses in patients with orbital lesions. Source: AAO

Posted on: Oct 3 2018
By: Saratoga Opthalmology
Leave a response

Surgical options appear comparable for intermittent childhood exotropia

In this large multicenter randomized trial, investigators evaluated the long-term outcomes of 2 surgical approaches for managing childhood intermittent exotropia (IXT): bilateral lateral muscle recession and unilateral recess-resect. Source: AAO

Posted on: Oct 2 2018
By: Saratoga Opthalmology
Leave a response

Early initiation of antiviral therapy benefits patients with CMV-associated anterior uveitis

Investigators of this consecutive case series report the characteristics of cytomegalovirus (CMV)-associated anterior uveitis and compared response with 2 types of antiviral treatments. Source: AAO

Posted on: Oct 1 2018
By: Saratoga Opthalmology
Leave a response

Positive outlook for patients with IIH and mild visual dysfunction

This study explored whether visual field mean deviation (MD) on standard static perimetry is a reliable predictor of visual outcome in patients with idiopathic intracranial hypertension (IIH). Source: AAO

Posted on: Sep 28 2018
By: Saratoga Opthalmology
Leave a response

Week in review: Luxturna, Novartis, NIDEK

This week, Luxturna approaches EU approval, Novartis’ brolucizumab outperforms aflibercept in neovascular AMD trials and NIDEK unveils a “groundbreaking” gonioscopy device that performs 360-degree iridocorneal angle imaging in full color. Source: AAO

Posted on: Sep 28 2018
By: Saratoga Opthalmology
Leave a response

Intra-arterial chemotherapy carries a low risk for complications

In this study, researchers compared complication rates arising from primary and secondary intra-arterial chemotherapy (IAC) treatment of retinoblastoma. Source: AAO

Posted on: Sep 27 2018
By: Saratoga Opthalmology
Leave a response

Alcon releases 5-year CyPass data

Stephen Lane, MD, shared full results from the post-approval COMPASS-XT study at the 2018 ESCRS meeting in Lisbon, Portugal. The long-term safety data offers new insights into Alcon’s decision to withdraw the CyPass microstent from global markets last month. Source: AAO